CY1107242T1 - Μυριστικο κητυλιο και παλμικο κητυλιο για τη θεραπεια του εκζεματος ή/και της ψωριασης - Google Patents
Μυριστικο κητυλιο και παλμικο κητυλιο για τη θεραπεια του εκζεματος ή/και της ψωριασηςInfo
- Publication number
- CY1107242T1 CY1107242T1 CY20081100293T CY081100293T CY1107242T1 CY 1107242 T1 CY1107242 T1 CY 1107242T1 CY 20081100293 T CY20081100293 T CY 20081100293T CY 081100293 T CY081100293 T CY 081100293T CY 1107242 T1 CY1107242 T1 CY 1107242T1
- Authority
- CY
- Cyprus
- Prior art keywords
- eczema
- treatment
- pulmony
- sports
- oxygen
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
Abstract
Στην παρούσα περιγράφεται η θεραπευτική αγωγή ανθρώπων ή άλλων θηλαστικών όσον αφορά το έκζεμα ή/και την ψωρίαση με τη χρησιμοποίηση δοσολογικών μορφών ή συνθέσεων που περιλαμβάνουν μυριστικό κητύλιο μεμονωμένα ή (σε πρόσμιξη ή κατ’ αλληλουχία) αμφότερα μυριστικό κητύλιο και παλμιτικό κητύλιο.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NZ50452500A NZ504525A (en) | 2000-05-12 | 2000-05-12 | Use of cetyl alcohol esters of myristic and palmitic acids to treat eczema and psoriasis |
NZ50722800 | 2000-09-28 | ||
EP01934672A EP1335719B1 (en) | 2000-05-12 | 2001-05-11 | Cetyl myristate and cetyl palmitate for treating eczema and/or psoriasis |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1107242T1 true CY1107242T1 (el) | 2012-11-21 |
Family
ID=26652173
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20081100293T CY1107242T1 (el) | 2000-05-12 | 2008-03-17 | Μυριστικο κητυλιο και παλμικο κητυλιο για τη θεραπεια του εκζεματος ή/και της ψωριασης |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP1335719B1 (el) |
AT (1) | ATE381327T1 (el) |
AU (2) | AU6083301A (el) |
CA (1) | CA2408541C (el) |
CY (1) | CY1107242T1 (el) |
DE (1) | DE60132008T2 (el) |
ES (1) | ES2298237T3 (el) |
WO (1) | WO2001085163A1 (el) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6696491B2 (en) * | 2000-05-12 | 2004-02-24 | Meracol Corporation Limited | Treating irritable bowel syndrome or disease |
US20030153620A1 (en) | 2000-05-12 | 2003-08-14 | Meakin Timothy David | Treating eczema and/or psoriasis |
NZ533370A (en) | 2004-06-03 | 2006-11-30 | Meracol Corp Ltd | Use of cetyl myristate and cetyl palmitate in therapy for multiple sclerosis |
EP2149375A1 (en) | 2008-07-28 | 2010-02-03 | Despharma Kft. | Compositions for the treatment of dermatological diseases, and uses thereof |
EP2543364A1 (en) | 2010-10-14 | 2013-01-09 | Deva Holding Anonim Sirketi | Formulations of cetyl myristate and/or cetyl palmitate |
EP2441446A1 (en) | 2010-10-14 | 2012-04-18 | Deva Holding Anonim Sirketi | Using of superdisintegrants in cetyl myristate and/or cetyl palmitate formulations |
EP2441445A1 (en) | 2010-10-14 | 2012-04-18 | Deva Holding Anonim Sirketi | Coating of cetyl myristate and/or cetyl palmitate particles |
EP2441441A1 (en) | 2010-10-14 | 2012-04-18 | Deva Holding Anonim Sirketi | A sieving method for cetyl myristate and/or cetyl palmitate |
EP2471528A1 (en) | 2010-12-29 | 2012-07-04 | Deva Holding Anonim Sirketi | A preparation method for suspension of cetyl myristate and/or cetyl palmitate |
EP2471385A1 (en) | 2010-12-29 | 2012-07-04 | Deva Holding Anonim Sirketi | Cetyl myristate and/or cetyl palmitate suspension formulations |
EP2471384A1 (en) | 2010-12-29 | 2012-07-04 | Deva Holding Anonim Sirketi | Suspension formulations of cetyl myristate and/or cetyl palmitate |
EP2471387A1 (en) | 2010-12-29 | 2012-07-04 | Deva Holding Anonim Sirketi | Cetyl myristate and/or cetyl palmitate suspension formulations |
EP2471386A1 (en) | 2010-12-29 | 2012-07-04 | Deva Holding Anonim Sirketi | Cetyl myristate and/or cetyl palmitate suspension formulations |
EP2471514A1 (en) | 2010-12-29 | 2012-07-04 | Deva Holding Anonim Sirketi | Controlled moisture content of cetyl myristate and/or cetyl palmitate granules or formulations |
EP2526931B1 (en) | 2011-05-23 | 2014-12-17 | Deva Holding Anonim Sirketi | Wet granulation methods of cetyl myristate and/or cetyl palmitate |
ES2538079T3 (es) | 2011-05-23 | 2015-06-17 | Deva Holding Anonim Sirketi | Distribución de tamaño de partícula del miristato de cetilo y/o palmitato de cetilo |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HU195729B (en) * | 1985-02-05 | 1988-07-28 | Sandoz Ag | Process for producing pharmaceutical compositions containing 9,10-dihydro-ergot-alkaloides |
DE4308282C2 (de) * | 1993-03-16 | 1994-12-22 | Beiersdorf Ag | Vorzugsweise in Form von Mikrosphärulen vorliegende galenische Matrices |
US5886038A (en) * | 1998-03-24 | 1999-03-23 | Panda Pharmaceuticals, L.L.C. | Composition and method for treatment of psoriasis |
DE19819273A1 (de) * | 1998-04-30 | 1999-11-11 | Pharmatec International S Giul | Pharmazeutische Ciclosporin-Formulierung mit verbesserten biopharmazeutischen Eigenschaften, erhöhter physikalischer Qualität und Stabilität sowie Verfahren zur Herstellung |
WO1999060167A1 (en) * | 1998-05-21 | 1999-11-25 | Isis Pharmaceuticals, Inc. | Compositions and methods for topical delivery of oligonucleotides |
GB9810949D0 (en) * | 1998-05-22 | 1998-07-22 | Hewlett Healthcare Limited | Formulation |
US6284234B1 (en) * | 1998-08-04 | 2001-09-04 | Johnson & Johnson Consumer Companies, Inc. | Topical delivery systems for active agents |
TR200103188T2 (tr) * | 1999-05-07 | 2002-04-22 | Pharmasol Gmbh | Sıvı ve katı lipit karışımları temelli lipid parçacıklar. |
US6696491B2 (en) * | 2000-05-12 | 2004-02-24 | Meracol Corporation Limited | Treating irritable bowel syndrome or disease |
-
2001
- 2001-05-11 ES ES01934672T patent/ES2298237T3/es not_active Expired - Lifetime
- 2001-05-11 AT AT01934672T patent/ATE381327T1/de active
- 2001-05-11 DE DE60132008T patent/DE60132008T2/de not_active Expired - Lifetime
- 2001-05-11 AU AU6083301A patent/AU6083301A/xx active Pending
- 2001-05-11 CA CA002408541A patent/CA2408541C/en not_active Expired - Fee Related
- 2001-05-11 EP EP01934672A patent/EP1335719B1/en not_active Expired - Lifetime
- 2001-05-11 AU AU2001260833A patent/AU2001260833B2/en not_active Ceased
- 2001-05-11 WO PCT/NZ2001/000085 patent/WO2001085163A1/en active IP Right Grant
-
2008
- 2008-03-17 CY CY20081100293T patent/CY1107242T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
EP1335719B1 (en) | 2007-12-19 |
CA2408541C (en) | 2009-07-28 |
ES2298237T3 (es) | 2008-05-16 |
DE60132008D1 (de) | 2008-01-31 |
CA2408541A1 (en) | 2001-11-15 |
AU6083301A (en) | 2001-11-20 |
WO2001085163A1 (en) | 2001-11-15 |
AU2001260833B2 (en) | 2005-09-29 |
DE60132008T2 (de) | 2008-12-11 |
EP1335719A4 (en) | 2004-02-25 |
ATE381327T1 (de) | 2008-01-15 |
EP1335719A1 (en) | 2003-08-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1107242T1 (el) | Μυριστικο κητυλιο και παλμικο κητυλιο για τη θεραπεια του εκζεματος ή/και της ψωριασης | |
CY1107615T1 (el) | Θεραπευτικοι συνδυασμοι αντιυπερτασικων και αντιαγγειογενετικων παραγοντων | |
ES2189235T3 (es) | 6-fenilfenantridinas sustituidas. | |
CY1108532T1 (el) | Ενωσεις και συνθεσεις για την παροχη δραστικων παραγοντων | |
PT882021E (pt) | Novas fenantridinas | |
CY1108610T1 (el) | Πεπτιδια της il-2 και παραγωγα αυτων και χρηση αυτων ως θεραπευτικοι παραγοντες | |
CY1106816T1 (el) | 1,5-δισυποκαταστημενες ενωσεις 3,4-διυδρο-1h-πυριμιδο [4,5-d] πυριμιδιν-2-ονης και η χρησιμοποιηση αυτων δια τη θεραπευτικη αγωγη ασθενειων εις τις οποιες μεσολαβει η csbp/p38 κιναση | |
CY1114133T1 (el) | ΥΠΟΚΑΤΕΣΤΗΜΕΝΕΣ γ-ΦΑΙΝΥΛ-Δ-ΛΑΚΤΑΜΕΣ ΚΑΙ ΧΡΗΣΕΙΣ ΠΟΥ ΣΧΕΤΙΖΟΝΤΑΙ ΠΡΟΣ ΑΥΤΕΣ | |
DE122006000010I2 (de) | Benzocyclobutyl- oder Indanyl-Alkyl-Amino-Alkyl substituierte 3-Benzazepin-2-ones, verwendbar in derBehandlung von kardiovaskularen Krankheiten | |
CY2014031I1 (el) | Τροποποιημενα 2’ και 3’-νουκλεοζιτικα προφαρμακα για θεραπεια μολυνσεων απο flaviviridae | |
CY1108874T1 (el) | ΧΡΗΣΗ ΤΩΝ ΑΝΑΣΤΟΛΕΩΝ Ι κΒ- ΚΙΝΑΣΗΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΠΟΝΟΥ | |
ATE232396T1 (de) | Oxydiertes thymosin beta 4 | |
CY1107424T1 (el) | Χρηση ενος αναστολεα ibat για τη θεραπευτικη αντιμετωπιση η προφυλαξη απο δυσκοιλιοτητα | |
GB0025173D0 (en) | Therapeutic agents | |
CY1108563T1 (el) | Μεθοδοι και υλικα για τη θεραπεια της ανεπαρκειας (ελλειψης) τεστοστερονης στους ανδρες | |
BR0210056A (pt) | composições e métodos para tratamento de hiperplasia | |
DE60132444D1 (de) | Behandlung von reizkolon-syndrom oder -krankheit | |
DK0889886T5 (da) | Hidtil ukendte, i 6-stilling substituerede phenanthridiner | |
PT705100E (pt) | Guanidinas substituidas terapeuticas | |
DE60116359D1 (de) | Kahalalid f formulierung | |
DE60112756D1 (de) | Racecadotril enthaltende trockene pulverformulierung | |
DE69612056T2 (de) | Terpenderivate (sarcodictyine) als antikrebsmittel | |
NO20032597D0 (no) | Anvendelse av SARP-1 for behandlingen og/eller forebyggingen av skleroderma | |
DE69230644T2 (de) | Verwendung von protease nexin-i als mittel gegen entzündungen | |
BR0015121A (pt) | Composição farmacêutica utilizável para o tratamento de inflamação em humanos, e, método de tratamento de inflamação |